Chronobiology, excessive daytime sleepiness and depression: Is there a link? by Chellappa, Sarah Laxhmi et al.
www.elsevier.com/locate/sleep
Sleep Medicine 10 (2009) 505–514Review Article
Chronobiology, excessive daytime sleepiness and depression: Is
there a link?
Sarah Laxhmi Chellappa a,c, Carmen Schro¨der b, Christian Cajochen c,*
aThe CAPES Foundation/Ministry of Education of Brazil, Caixa Postal 365, CEP. 70359-970, Brasilia–DF, Brazil
bDepartment of Psychiatry and Behavioural Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305-5550, USA
cCentre for Chronobiology, Psychiatric University Clinics, Wilhelm Kleinstrasse 27, CH-4025 Basel, Switzerland
Received 5 February 2008; received in revised form 30 April 2008; accepted 2 May 2008
Available online 27 September 2008Abstract
The complaint of excessive daytime sleepiness (EDS), commonly encountered in clinical practice, may arise from a variety of
psychiatric disorders, most importantly depression. Even though EDS frequently leads depressed patients to seek medical assistance,
it is commonly under-evaluated and under-diagnosed. Therefore, a comprehensive understanding and management of EDS is essen-
tial in the clinical assessment of depression. Within a theoretical framework, a chronobiological approach may shed new light on the
complex interaction of EDS and depression. In this review, studies on EDS and depression are summarized and discussed within the
context of circadian and sleep regulatory mechanisms. Furthermore, potential chronobiological therapeutic strategies are proposed
to address some of the unmet needs in the treatment of EDS and depression.
 2008 Elsevier B.V. All rights reserved.
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Excessive daytime sleepiness (EDS) is a tendency to
fall asleep despite volitional attempts to remain alert.
Chronic sleep loss and/or poor sleep quality are the
major underlying reasons for EDS. They occur in numer-
ous sleep disorders, such as obstructive sleep apnea and
narcolepsy, as well as in psychiatric disorders, particu-
larly depression. Approximately 80% of depressive states
are associated with comorbid insomnia, related or not to
EDS [1]. Depressed patients exhibit a plethora of com-
plaints related to daytime energy levels. However, even
though sleep quality and quantity are very often substan-
tially decreased in depression, patients do not necessarily
have a higher propensity to fall asleep during the day, but
rather experience a subjective state of sleepiness [1,2].
This state of sleepiness in depression diﬀers from EDS1389-9457/$ - see front matter  2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.sleep.2008.05.010
* Corresponding author. Tel.: +41 613255318; fax: +41 613255577.
E-mail address: Christian.Cajochen@upkbs.ch (C. Cajochen).as typically encountered in narcolepsy and obstructive
sleep apnea (OSA). In the former, subjects experience
EDS as ‘‘sleep attacks,” namely short and recurrent peri-
ods of sleep in the daytime, regardless of the prior
amount or quality of night sleep. In OSA, there is a
higher propensity to fall asleep during the daytime, pos-
sibly due to sleep fragmentation and/or hypoxemia
related to chronic intermittent respiratory events [3].
There is ample evidence for an association between
daytime sleepiness and moderate to severe depression
[4,5]. Given that insomnia, particularly when associated
with impaired daytime function, plays a key role in the
onset of depression [6], it is of signiﬁcant clinical impor-
tance to unravel the link between EDS and depression.
Furthermore, knowledge on the inter-relation between
EDS and mood disorders may have ramiﬁcations for
the treatment of depression [7,8].
Apart from the sleep perspective, circadian rhythms
play a key role in the association between depression
and EDS. Depression is strongly intertwined with bio-
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includes neurobiological systems that underlie both the
pathophysiology of depression, such as the serotonergic
system, as well as the clinical aspects of depression [9].
This rhythmicity can manifest itself as an intra-episodic
symptomatic expression – such as diurnal variation of
mood and early morning awakening – or as an inter-epi-
sodic expression – such as seasonal recurrence of clinical
depression or reappearance after therapeutic manage-
ment. Disorders of the human circadian system per se
can result in circadian misalignment, leading to sleep
disturbances (namely, insomnia and/or EDS), reduced
attention and impaired daytime alertness, lack of
energy, lower performance, negative mood and gastroin-
testinal disorders. Interestingly, these symptoms also
occur in depression, which further extends the idea that
depression and circadian rhythms are intimately con-
nected. Among depressive disorders, major depression,
bipolar depression and seasonal aﬀective disorder are
deﬁned as being both episodic and recurrent, thus possi-
bly reﬂecting a chronobiological disorder [10]. Together
with the rhythmicity of clinical symptoms, the afore-
mentioned disorders have been associated with altera-
tions of the rhythm of several physiological variables.
These include sleep–wake cycle disruption and patho-
physiological changes in the secretion of an array of hor-
mones, including cortisol, TSH, GH and melatonin,
among others [11–14].
The application of chronobiological and sleep regula-
tory concepts in the treatment of depressive disorders
has led to eﬀective therapeutic strategies, among which
bright light therapy and sleep deprivation can be high-
lighted [9,11]. Furthermore, there is evidence that the
circadian system is implicated in pharmacological treat-
ment mechanisms, such as lithium therapy for bipolar
depression [15]. Lithium can modify the phase-angle
between circadian temperature rhythm and rest–activity
cycle and lengthens the period of circadian rhythms by
increasing the circadian period of ﬁring rate rhythms
of SCN neurons in a concentration-dependent manner
[16,17]. Therefore, the stabilization of circadian rhythms
may be a key action of clinically eﬀective mood-stabiliz-
ing treatments.
In this review, studies on EDS and depression will be
summarized and discussed within the framework of cur-
rent sleep and chronobiology perspectives. A brief out-
look of the probable chronobiological underpinnings
will be given in order to provide insights on this inter-rela-
tionship and possibilities of chronobiological therapies.
2. EDS and depression
EDS is a common complaint in clinical practice [18].
On the societal level, the negative impacts of sleepiness
are likewise signiﬁcant. For instance, in the USA, a siz-
able proportion of adults (43%) report that they are sosleepy during the day that it interferes with their daily
activities, with one out of ﬁve individuals experiencing
this level of daytime sleepiness at least a few days per
week or more [19]. On the individual level, EDS not only
reduces personal eﬃciency of labour, but also leads to
diﬃculties with concentration, memory and mood
impairment, which further negatively impact perfor-
mance and well being [2,18,20].
EDS is commonly viewed as a cardinal sign of dis-
turbed or inadequate sleep, and can be directly linked
to depression [4,5]. In a recent study conducted with a
random sample of 16,500 individuals in the USA,
8.7% displayed EDS [21]. Strikingly, EDS was more
strongly associated with depression (OR = 3.12) than
with obesity or other metabolic factors and sleep-related
breathing disorders. Indeed, depressive disorders are
often associated with disrupted sleep. While the majority
of depressed patients with sleep disruption suﬀer from
insomnia, a considerable number of them report hyper-
somnia with concomitant daytime sleepiness [22]. This
subset of patients is often diagnosed with bipolar
depression or depression with DSM-IV-TR atypical fea-
tures which include irritability, increased appetite and
sleepiness [23].
Recently, we observed a signiﬁcant association
(r = 0.80) between EDS and suicidal ideation in
depressed patients [24]. This unequivocal result was
striking, considering that no speciﬁc relation of EDS
with suicidal ideation had been previously described.
An explanation for this ﬁnding may be that patients
with severe depressive disorder rank daytime sleepiness
in line with other major depressive symptoms [25–27].
If these ﬁndings are conﬁrmed in a larger sample size,
EDS should, therefore, be considered in the assessment
of suicidal risk in depression.
Despite the signiﬁcant evidence linking EDS to
depression, the mechanisms underlying this relationship
remain uncertain to date. One important line of research
builds upon ﬁndings from several large-scale epidemio-
logical studies, which have demonstrated that approxi-
mately 20% of depressed patients exhibit a frequently
undiagnosed sleep-disordered breathing, mostly
obstructive sleep apnea [28,29]. This goes in line with a
large number of reports which have gathered data link-
ing metabolic syndrome and, most importantly, obesity
and diabetes or insulin resistance, together with elevated
inﬂammatory markers, to both sleep-disordered breath-
ing and depression [30–36].
3. Depression and circadian rhythms
Diurnal variations of mood and sleep disturbances
belong to the core of classical symptoms that have
linked depression to the circadian system [37]. Typical
mood variation consists of a substantially improved
mood in the evening in contrast to worsening in the
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ing includes other spheres, such as psychomotor activity
and cognitive performance [39,40]. The existence of this
type of daily variation is a predictor for positive
response to certain types of treatment, such as sleep
deprivation [41]. However, this pattern does not occur
in all subtypes of depression and the opposite has also
been described, particularly for bipolar depression and
atypical depression [10]. In a given patient, diﬀerent pat-
terns of diurnal mood variation can occur during a sin-
gle depressive episode.
Shortening of REM sleep latency and an abnormal
distribution of REM sleep throughout the night may
typically occur in depression [42–44]. In atypical depres-
sion, hypersomnia is frequent, with increased night sleep
duration up to 12 h, combined or not with EDS [24].
Since both REM sleep and sleep duration are under
strong circadian control, these sleep alterations may
reﬂect disturbances in the circadian system of depressed
patients. There is a considerable body of evidence sug-
gesting that daytime sleep may occur in depressed
patients more frequently than commonly thought, possi-
bly as a consequence of a dampened circadian rhythm of
sleep propensity. In normal subjects, daytime napping
can result in nocturnal sleep changes similar to those
seen in depressed patients [1,21]. Thus, the nocturnal
sleep disturbance in depression may actually reﬂect the
occurrence of daytime naps with slow-wave sleep or
slow-wave EEG activity [44].
Seasonal Aﬀective Disorder (SAD) illustrates how an
alteration between the external light–dark cycle (i.e.,
photoperiod) and circadian rhythms may elicit a depres-
sive disorder. Most SAD patients become depressed in
the winter time because of the later dawn, which leads
their circadian rhythms to delay with respect to both
clock time and to the sleep–wake cycle [45]. Changes
in the latter sleep–wake are apparent, with most patients
presenting hypersomnia in conjunction with EDS.
Abnormalities in the circadian rhythm are also
observed in non-seasonal depressed patients, including
variations in the circadian phase and amplitude of core
body temperature [9,38] and the endogenous melatonin
rhythm [51,14]. Though overall studies have yielded
conﬂicting results, chronobiological studies in which
sleep timing and/or total amount of sleep were re-sched-
uled in patients provide evidence for the implication of
circadian rhythms in depression [46,47]. However, it is
still unclear whether these observations represent func-
tional changes of the circadian system itself or are due
to the inﬂuence of other factors downstream.
One critical aspect in major depression is the hyperac-
tivity of hypothalamus–pituitary–adrenal (HPA) axis
which reﬂects a stress response and/or abnormality of
the circadian rhythm of cortisol [48]. Usually, the acro-
phase of the cortisol rhythm occurs early in the morning
prior to awakening, while the nadir is registered at night,a short time after initiating sleep [12]. However, in
depressive states, HPA hyperactivity leads to sustained
high levels of cortisol resulting in insomnia and a hyper-
arousal state [13]. Furthermore, depressive patients
often present high levels of thyrotropin-releasing hor-
mone (TRH), and a reduction of the normal nocturnal
elevation of serum thyrotropin has been suggested as a
marker of an abnormal circadian rhythm of this hor-
mone in depressive states [49]. As a consequence, hypo-
thyroidism may be an additional factor for high levels of
subjective sleepiness during daytime.
In addition to circadian and endocrine changes in
depression, recent imaging studies have shed new light
on the neurobiological basis of depression. The
increased magnitude of ultradian (i.e., within-day) mood
variability in depressed patients compared with non-
depressed subjects [52] may be related to regional cere-
bral metabolic changes in the evening relative to morn-
ing and may reﬂect functional changes in components of
the ventral and dorsal emotion neural systems [53].
Diurnal variation in mood may be related to diﬀerent
patterns of diurnal changes in the regional cerebral met-
abolic rate of glucose (rCMRglc) in depressed and
healthy subjects. Morning-to-evening changes in
rCMRglc diﬀer with regard to the brain systems that
promote wakefulness. In healthy adults, relative
rCMRglc increases during the evening compared to
the morning in wake-promoting brainstem and hypo-
thalamic regions [54]. This pattern may reﬂect an input
from the circadian timing system to promote wakeful-
ness in face of the increasing sleep pressure. Considering
that circadian rhythms can be attenuated in depression,
diurnal variations in rCMRglc in brainstem and hypo-
thalamic areas may be, therefore, blunted in depressed
compared to healthy individuals [55].
4. Sleepiness, mood and chronobiology: bridging the gap
From a conceptual point of view, EDS can be consid-
ered to result from the biological need for sleep as char-
acterized by a complex interaction between circadian
and homeostatic processes [8]. Brieﬂy, the master pace-
maker driving circadian rhythms, the suprachiasmatic
nuclei (SCN), is synchronized to the external light–dark
cycle through retinal light input (light being the main
synchronizer or ‘‘zeitgeber”) [56]. A specialized non-
visual retinohypothalamic tract provides direct neuronal
connection to the SCN from novel photoreceptors in the
retinal ganglion cells that measure illuminance [57,58].
Although the SCN is the so-called master clock, circa-
dian oscillators have been found in practically every cell
[59]. Therefore, the SCN would act in a manner to orga-
nize an internal temporal conjunction of several periph-
eral oscillators. The homeostatic component is
dependent on the duration of prior wakefulness and is
dissipated during sleep, reinitiating its build-up during
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of sleep regulation has uniﬁed these two components
to understand the timing and architecture of sleep [61].
This model can also be utilized to describe possible dis-
turbances in either process during depression. The clin-
ical sleep disturbance with early morning awakening
could arise from an impaired build-up of S during wak-
ing (diminished sleep pressure) or an earlier timing of
process C. Other possible abnormalities could lie in
the decline of S during sleep or altered circadian period,
phase, or amplitude [37].
Considering that mood is such a complex phenome-
non, modulated by a plethora of factors extending from
hormones to social situations, insight into its regulation
is a rather diﬃcult task. Surprisingly, though, mood is
also determined by circadian and homeostatic factors
[62,63]. Several hypotheses have been proposed to
explain the mechanisms that underlie the relationship
of sleep, sleep disorders and depression. According to
the internal coincidence hypothesis, an abnormal rela-
tionship between the circadian system and the sleep–
wake cycle occurs in which the phase-angle between an
advanced circadian pacemaker and the sleep–wake cycle
is depressogenic [64]. In other words, depressive patients
sleep at the wrong biological clock-time. Thus, such
patients commonly develop insomnia that may be asso-
ciated with EDS. On the other hand, the S-deﬁciency
model proposes a deﬁcient build-up of process S (i.e.,
sleep need) in depression, with process C remaining
unaﬀected [60]. A third hypothesis suggests that dis-
turbed neurochemical interaction mechanisms underlie
abnormalities in the ultradian rhythm of REM sleep in
depressed patients [37].
Two important protocols have been developed in
order to dissect out the relative contributions of circa-
dian and sleep homeostatic processes in humans, namely
the constant routine and the forced desynchrony proto-
cols [65]. In the ﬁrst procedure, the amplitude and phase
of many circadian rhythms can be elucidated without
the masking eﬀects of motor activity, meals and light
conditions. In the second protocol, subjects live on arti-
ﬁcially very long or very short days, so that the circadian
system is no longer entrained to the imposed sleep–wake
cycle, enabling the measurement of an individual’s circa-
dian period. The desynchronized subjects sleep at diﬀer-
ent circadian phases of the entire 24-h cycle, and
subsequent analyses can diﬀerentiate the relative contri-
bution of the sleep homeostat or the biological clock to
a given variable [66]. Usually – but not always – both
factors contribute substantially to subjective measures,
such as mood, sleepiness and neurobehavioral perfor-
mance [67,68]. However, only few studies have used
these techniques in a controlled manner to unmask the
contribution of the circadian clock in depression. These
protocols can certainly contribute to a more accurate
understanding of the circadian disruptions that occurin depression, and, thus, can be of substantial value in
future research [9]. Table 1 gives an overview of constant
routine and forced desynchrony studies in depressed
patients [69–72,67,73].
5. Further hypotheses: sleepiness, neurotransmitters and
hyperarousal
Sleepiness may be deemed as a physiological state or
urge, that promotes the onset of sleep, and which is
reversed or satiated (although not always) by the attain-
ment of adequate sleep. The neurobiological substrates
of sleepiness are not understood completely. Sleepiness
may reﬂect the waning of processes maintaining wake-
fulness or it may result from distinct neural systems act-
ing to promote sleep [74]. In other words, these
neurological substrates interact in a complex fashion
to generate sleep and wakefulness. For instance, accord-
ing to the ‘‘ﬂip–ﬂop” model of sleep and wakefulness
[75], monoaminergic nuclei, including the locus coeru-
leus, the serotonergic dorsal and median raphe´ nuclei
and the histaminergic tuberomammilary neurons, pro-
mote wakefulness by direct excitatory eﬀects on the cor-
tex and by inhibition of sleep promoting neurons of the
ventrolateral preoptic nucleus. During sleep, the latter
inhibits monoaminergic-mediated arousal regions
through GABAergic and galaninergic projections. Orex-
in-containing neurons seem to play an important stabi-
lizing role in the proposed ‘‘ﬂip–ﬂop” mechanism. On
the other hand, the accumulation of a sleep-promoting
substance that enhances the activity of sleep-promoting
cells and reduces the activity of wake-promoting neu-
rons may be a potential mechanism for homeostatic
sleep regulation [75]. However, it remains to be deter-
mined how these and other brain structures act and
interact to generate EDS in various disorders.
Circadian rhythms involve the same neurotransmit-
ters that have been postulated to be important for
depression, such as serotonin, thus leading to a situation
in which changes in one system have repercussions on
the other [9]. Serotonin plays an important part in sleep
regulation, and prefrontal cortical serotonin has been
linked to mood. All these inter-relationships have been
conceptualized in a dual model whereby circadian
rhythms and serotonin [76] together are involved in a
system vulnerable to depression through genetic, hor-
monal and light exposure factors [9,11,37,62,77].
From a pathophysiological standpoint, sleep distur-
bance in depressed patients with a chief complaint of
daytime sleepiness appears to be associated with a cen-
trally driven hyperarousal, whereas idiopathic sleepiness
is usually associated with a centrally driven hypoarous-
al. This hypothesis has been supported by recent work in
which both groups exhibited diﬀerences in night time
sleep and daytime alertness [78]. The main postulation
was that these disorders are related to the altered arou-
Table 1





Protocol procedure Circadian marker Phase/amplitude/phase
angle changes
in depressed
Dahl et al. (1993) [69] CR 6 SDa 6 CTb SAD 27-h CR DLMOc CBTd DLMO & CBT
phase-delay
Buysse et al. (1995) [70] CR 26 UP 17 CT DSM-IV
unipolar
depressione
36-h CR CBT melatonin
cortisol
No diﬀerences
Wirz-Justice et al. (1995) [71] CR 11 SD 8 CT SAD 40-h CR CBT melatonin No diﬀerences
Avery et al. (1997) [72] CR 6 SD 6 CT SAD 27-h CR CBT cortisol CBT & cortisol
phase-delay
Koorengevel et al. (2002) [67] FD 7 SD 7 CT SAD 120-h FD (six 20-h days) CBT melatonin CBT amplitude ;
Koorengevel et al. (2003) [73] FD 7 SD 7 CT SAD 120-h FD (six 20-h days) CBT melatonin CBT amplitude ;
a Seasonal depressed.
b Control subjects.
c Dim light melatonin onset.
d Core body temperature.
e Unipolar depression.
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by the fact that idiopathic sleepiness is usually associ-
ated with dysfunction of the autonomic nervous system
such as orthostatic hypotension and hypoactivity of the
corticotropin-releasing hormone neuronal system (that
is directly linked to arousal), whereas psychiatric hyper-
somnia is most frequently related to depression and anx-
iety, conditions deemed to be associated with
hyperarousal [79]. However, more research on physio-
logical parameters, such as metabolic rate and tempera-
ture, is required to test the hypothesis that sleepiness in
depression, and idiopathic sleepiness are disorders of
arousal.
6. Diagnosis of EDS
Although daytime sleepiness is highly prevalent, it
is frequently under-diagnosed. To tackle this problem,
the diagnosis of EDS should start with a precise def-
inition and clinical history. EDS can result from the
interaction of three following factors that account
for increased sleepiness: physiological (due to the
interplay of circadian and homeostatic components,
as detailed above), manifest and introspective sleepi-
ness [80]. Manifest sleepiness refers to the behavioural
correlate of the physiological need for sleep. Reduced
performance and alertness in a sleepy individual,
involuntary sleepiness despite volitional attempts to
remain awake and low performance in cognitive and
behavioural tests can be some of the main hallmarks
of ‘‘manifest sleepiness” in non-medicated depression.
Manifest sleepiness is modulated by individual
motivation and environmental factors. Introspective
sleepiness consists of the individual ability to charac-
terize internal subjective state [80]. In healthy subjects,
there is an adequate perception of sleepiness aftersustained sleep deprivation. Nevertheless, in chronic
sleep deﬁcit due to clinical disorders such as depres-
sion, the perception of sleepiness may be dramatically
reduced, thus leading to an underestimation of sleepi-
ness [6].
Depressed patients may present subjective complaints
of tiredness or fatigue instead of more speciﬁc symptoms
of sleepiness. In order to discriminate between tiredness
and sleepiness, questions regarding the need to take
naps, dozing in passive situations, or how long it is
needed to initiate sleep at usual bedtime can help to dis-
tinguish real sleepiness from less speciﬁc complaints
[1,20,81]. Problems concerning performance or neuro-
cognitive function are often completely ignored. Perfor-
mance alone may not always be the best indicator of
sleepiness, as motivation may temporarily override a
performance decrement. Compensatory strategies may
also be invoked, such as avoiding increased errors by
adopting a slower pace [82]. Likewise, individuals might
also accept lower levels of achievement. An accurate
evaluation of EDS usually requires several assessment
methods [22]. A wide array of tools has been developed
to assess sleepiness in a more objective fashion, although
all of them have their shortcomings. Initially, introspec-
tive behavioural scales and performance tests were uti-
lized to assess sleepiness. Subjective scales try to
analyze the perception of alertness/sleepiness. However,
a serious limitation to this approach is that patients
must have an insight into their problem and be able to
distinguish sleepiness from other factors aﬀecting per-
formance, which may not be the case. On the other
hand, scales, such as the Stanford Sleepiness Scale and
the Karolinska Sleepiness Scale, can convey an appro-
priate assessment of the momentary degree of alert-
ness/sleepiness [83,84]. Furthermore, they are quite
useful in tracking symptoms over time, although they
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Epworth Sleepiness Scale oﬀers a better method for
assessing overall sleepiness, since it reports on sleepiness
over a one-month period, including both active and pas-
sive situations of possible behavioural sleepiness [85].
Visual analogue scales require the subject to provide a
response along a linear 100 mm line, ranging from very
sleepy to very alert [6]. The main advantage of these
scales is that they can be utilized often and sequentially
to track subtle changes in the feeling of sleepiness over a
given time period. Performance tests, such as the PVT,
have been frequently utilized to measure sustained atten-
tion [86]. However, questionnaires utilized in the assess-
ment of subjective sleepiness (e.g., Epworth or Stanford
scales) do not always correlate with objective quantiﬁca-
tions. Objective tests of daytime sleepiness rely on mea-
surement of physiological parameters, the most
extensively used test being the multiple sleep latency test
(MSLT). The MSLT is performed after an overnight
polysomnogram in order to assess sleep during the prior
night (which controls for nocturnal sleep disruption that
could account for daytime symptoms, such as obstruc-
tive sleep apnea) [87]. Accordingly, mean sleep latency
>10 min is deemed normal, the 5–10 min range as a grey
zone and <5 min as severe daytime sleepiness.
Waking EEG changes may also provide insight into
the state of sleepiness in depression. For instance, in a
40-h constant routine study looking at the EEG and
subjective sleepiness in seasonal aﬀective disorder
(SAD), we observed that the progressive build-up of
sleepiness was considerably reduced in SAD patients
[88]. The time course of waking EEG theta–alpha activ-
ity showed a rapid increase during the ﬁrst 10 h, which
then remained constant, in contrast to control subjects
who showed a slower continuous exponential increase
in the course of the 40-h episode of sustained wakeful-
ness. Given that this pattern was independent of clinical
state or season, SAD patients may have a trait deﬁciency
in the homeostatic build-up of sleep pressure.Table 2
Chronobiological therapies of depressive disorders
Total sleep deprivation (TSD)
Partial sleep deprivation (PSD) in the second half of the night
Repeated TSD or PSD
Repeated TSD or PSD with antidepressant therapy
Sleep–wake cycle phase advance
TSD followed by sleep phase advance
Single or repeated TSD or PSD followed by light therapy
Single or repeated TSD or PSD followed by phase advance and light therap
Single or repeated TSD or PSD combined with lithium or serotonin selectiv
Light therapy (winter seasonal MDD)
Light therapy (non-seasonal MDD)
Light therapy combined with serotonin selective reuptake inhibitors (non-se
*Modiﬁed by Wirz-Justice et al. (2005) [81].
MDD, major depressive disorder.7. Chronobiological treatments for sleepiness and
depression
A chronobiological approach may address some of
the unmet needs in the treatment of depression, such
as diminishing the latency of onset of antidepressant
action, reducing residual symptoms and preventing
relapse in the long-term. Circadian rhythm and sleep
research have led to promising non-pharmacological
therapies [9,11,89]. Sleep deprivation therapy exerts a
rapid and dramatic, albeit usually short-lasting,
improvement of mood in the majority of patients with
major depressive disorder. Light therapy has been
applied to a wide range of mood disorders as stand-
alone therapy or as an adjunct to antidepressant phar-
macotherapy [90]. Light acts as a synchronizing agent
for disturbed circadian rhythms, while sleep deprivation
challenges the sleep–wake homeostat [91,92]. Table 2
summarizes the main chronobiological therapies
employed for depressive disorders.
Total sleep deprivation (TSD) for one whole night
improves depressive symptoms in 40–60% of treatments
[37,92]. The degree of clinical change spans a continuum
from complete remission to worsening. Sleep depriva-
tion (SD) response shows up in the SD night or on the
following day. After recovery sleep, 50–80% of ﬁrst
day responders suﬀer a complete or partial relapse; nev-
ertheless, improvement can last for weeks. Sleep seems
to lead to the relapse, although this may not necessarily
be the case. Treatment eﬀects may be stabilized by anti-
depressant drugs, lithium, shifting of sleep time or light
therapy [93]. Current opinion is that partial sleep depri-
vation (PSD) in the second half of the night is equally
eﬀective as TSD. Sleep deprivation may hasten the onset
of antidepressant medication action and repeated trials
of SD can also be an eﬃcient treatment strategy in drug
refractory depression [37,91,92]. Given that insomnia
associated or not with EDS is such a prominent feature





3 days Up to 2 weeks
Hours Up to 2 weeks
Hours Weeks/months
y Hours Weeks/months
e receptor inhibitors Hours Months
Days Weeks/months
Weeks Weeks/months
asonal MDD) Up to 2 weeks Weeks/months
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deprivation therapy for depression.
Light per se exerts powerful non-visual eﬀects on a
wide range of biological functions including the modula-
tion of human alertness levels. Factors such as the dose
(illuminance levels), exposure duration, timing and
wavelength of light have important repercussions on
the alerting response to light in humans and can lead
to a substantial decrement in sleepiness [94]. Bright light
therapy is characterized by a fast onset of antidepressant
action and by additive properties to antidepressant med-
ication [95]. Bright light therapy, beginning in the morn-
ing after partial sleep deprivation, has been
demonstrated to prevent depressive relapse after recov-
ery sleep in sleep deprivation responders [95]. Although
until now bright light therapy has been regarded as a
ﬁrst-line treatment only for seasonal aﬀective disorder
(SAD) [96], recent studies on non-seasonal depression
and the Cochrane meta-analysis on light therapies for
this type of depression have provided evidence for the
eﬃcacy of bright light as an adjuvant to antidepressant
pharmacotherapy [94,97,95,98]. Taking into account the
insuﬃcient remission rate of depression solely with
pharmacotherapy and the favourable risk-to-beneﬁt
ratio of light therapy, it can oﬀer a promising non-phar-
macological biologically oriented treatment approach
[90].
The combination of treatment strategies that manip-
ulate circadian rhythms has lead to some very promising
results. A strategy to block relapse in successful sleep
deprivation responders includes therapeutic interven-
tions combining sleep deprivation, phase advance and
light therapy. For instance, one combination encom-
passes total sleep deprivation plus phase advance [44].
The underlying assumption is that, after a successful
sleep deprivation, the avoidance of recovery sleep during
a hypothesized critical early morning time period may
prevent sleep deprivation associated relapses, with a
concomitant improvement in both mood and subjective
sleepiness [99].
On the pharmacological domain, the use of modaﬁ-
nil, a wake-promoting agent, has been recently sug-
gested as a well-tolerated adjuvant in the treatment of
EDS and depression, with a substantial improvement
in both mood and sleepiness [100]. Furthermore, it is a
particularly attractive alternative to other stimulants
because of its low abuse potential. However, in a dou-
ble-blind placebo control study, no signiﬁcant improve-
ments for daytime sleepiness, depression scores or
overall clinical state were found [101]. Thus, caution
should be kept in mind when using modaﬁnil in
depression.
Regarding antidepressants, some of the therapeutic
properties of selective serotonin (5-HT) reuptake–inhib-
iting (SSRI) drugs can be related to the 5-HT2C receptor
subtype, and it is interesting to observe that 5-HT2Creceptor agonists in the rat SCN mimic the eﬀects of
light [50]. Serotonergic drugs may thus improve
entrainment.
Recently, a novel antidepressant drug, agomelatine, a
melatonin agonist and 5-HT2c antagonist, targeted both
the circadian system and mood. Agomelatine [102] has
identical physiological actions to melatonin [103] when
administered in the evening to advance circadian phase
and to promote a rapid sleep onset without after-eﬀects
on the following day. Indeed, unlike other antidepres-
sants, notably SSRIs, agomelatine does not lead to
insomnia, fragmentation of slow-wave sleep and night-
mares, but rather improves the quality of sleep, with
possible increases in both slow-wave sleep, and to a
lower extent, REM sleep in depressed patients [104].
The interesting aspect of this treatment is that its core
action aims at the circadian system, and it has been
shown to be especially useful for synchronizing circa-
dian rhythms of body temperature, cortisol and thy-
roid-stimulating hormone secretion [102]. Considering
this, agomelatine can be indicated for the management
of depression associated with EDS.
Recently, orexin-antagonists Ox1 and Ox2 receptors
are being tested in the treatment of insomnia. Orexins
are hypothalamic peptides that may play an important
role in maintaining wakefulness in mammals. When
administered during the active period of the circadian
cycle, a dual antagonist of both orexin OX1 and OX2
receptors was shown to increase subjective and objective
EEG sleep in humans [105]. Although this study tar-
geted narcolepsy, these results may open new perspec-
tives for investigating the role of endogenous orexins
in sleep–wake regulation. Given the central role played
by orexins in regulating sleep–wake cycles, it has been
suggested that several sleep disorders may be associated
with maladaptive orexinergic tone [105]. Whether orex-
in-antagonists can be utilized for other types of sleep
disturbances, such as insomnia in depressed patients,
however, remains to be answered.
8. Conclusions
EDS is a complaint frequently encountered in depres-
sion. Notwithstanding the signiﬁcant evidence that links
EDS to depression, the underlying mechanisms of this
relationship remain uncertain. Considering that depres-
sion is intertwined with circadian rhythms on a wide
array of dimensions, a chronobiological approach may
shed new light on the complex interaction of EDS and
depression and oﬀer promising therapeutic strategies.References
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